Integrated gene therapy successfully treated Haemophilia A in India, providing long-term relief without bleeding episodes for ...

Researchers study long-term safety of lentiviral gene therapy in primates, finding no evidence of somatic mutations or ...

Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City ...

BHUBANESWAR: In a significant medical breakthrough, India’s first human gene therapy with a lentiviral vector for severe ...

PM-359 is a gene-modified cell therapy commercialized by Prime Medicine, with a leading Phase II program in Chronic Granulomatous Disease.

IMA-203 is a gene-modified cell therapy commercialized by Immatics, with a leading Phase II program in Ovarian Cancer;Endometrial Cancer.

To address the existing challenges with CAR T-cell therapy, scientists at Umoja Biopharma Inc. developed the Vivovec platform, which is an off-the-shelf surface-engineered lentiviral vector (LVV) drug ...

CDMO's Cell and Gene Center of Excellence Achieves fifth commercial viral vector product approval, and second overall from FDA in 2024 SEATTLE, WA and MILAN, ITALY / ACCESSWIRE / December 12, 2024 / ...

The Post Office scandal continues to have a "severe" impact on the mental health and lives of the loved ones of victims, new ...

Research led by Christian Medical College in Vellore, India, has demonstrated the successful use of lentiviral vectors to ...

Haemophilia is a severe bleeding disorder caused by the deficiency of clotting Factor VIII, leading to spontaneous internal ...

In a significant medical feat, Indian scientists have developed the first-in-human gene therapy using lentiviral vectors for ...